

Genoptix, Bionano Genomics strategic alliance, 8/17

August 2017—Genoptix and Bionano Genomics announced an exclusive agreement to co-develop information-rich diagnostics for selected hematologic oncology indications in the United States using Bionano's Saphyr system.

The Saphyr system accurately visualizes the structure of a genome from a simple DNA sample isolated directly from cancer cells, removing the need for cell culture. It allows for the detection of all major types of structural variants with a sensitivity greater than sequencing-based methods and with a much higher resolution than karyotyping or fluorescence in situ hybridization can provide, according to the company.

The development efforts will focus on indications within hematology-oncology in which detection of large structural variations of the genome is required for accurate diagnosis.

[Genoptix](#), 800-755-1605

[Bionano Genomics](#), 858-888-7663